Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Long Tang

Showing results (551-560 of 575) with videos related to

Pageof 58
Sort By:
Molecular Cancer|January 12, 2021
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responsesYu-Pei Chen, Jia-Wei Lv, Yan-Ping Mao, et al.
BMJ (Clinical Research Ed.)|February 6, 2023
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2018
Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized TrialsYu-Pei Chen, Ling-Long Tang, Qi Yang, et al.
Journal of the National Cancer Institute|October 23, 2020
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaYuan Lei, Ying-Qin Li, Wei Jiang, et al.
Cancer Cell|February 28, 2025
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trialCheng Xu, Guan-Qun Zhou, Wen-Fei Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trialCheng Xu, Si-Yang Wang, Man Nie, et al.
BMJ (Clinical Research Ed.)|March 31, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trialShun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, et al.
Med (New York, N.Y.)|February 14, 2026
Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinomaCheng Xu, Ze-Qi Lin, Yu-Zhe Wang, et al.
Nature Medicine|June 6, 2023
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatmentJiawei Lv, Yuan Wei, Jian-Hua Yin, et al.
Cell Research|July 21, 2020
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinomaYu-Pei Chen, Jian-Hua Yin, Wen-Fei Li, et al.
Pageof 58

Showing results (551-560 of 575) with videos related to

Sort By:
Pageof 58
Molecular Cancer|January 12, 2021
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responsesYu-Pei Chen, Jia-Wei Lv, Yan-Ping Mao, et al.
BMJ (Clinical Research Ed.)|February 6, 2023
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2018
Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized TrialsYu-Pei Chen, Ling-Long Tang, Qi Yang, et al.
Journal of the National Cancer Institute|October 23, 2020
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaYuan Lei, Ying-Qin Li, Wei Jiang, et al.
Cancer Cell|February 28, 2025
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trialCheng Xu, Guan-Qun Zhou, Wen-Fei Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trialCheng Xu, Si-Yang Wang, Man Nie, et al.
BMJ (Clinical Research Ed.)|March 31, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trialShun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, et al.
Med (New York, N.Y.)|February 14, 2026
Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinomaCheng Xu, Ze-Qi Lin, Yu-Zhe Wang, et al.
Nature Medicine|June 6, 2023
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatmentJiawei Lv, Yuan Wei, Jian-Hua Yin, et al.
Cell Research|July 21, 2020
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinomaYu-Pei Chen, Jian-Hua Yin, Wen-Fei Li, et al.
Pageof 58